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Key messages
What is already known about this subject?
 ► There is a relationship between statins and 
osteoporosis.
What does this study add?
 ► Osteoporosis is underrepresented in low-dose 
statin treatment.
 ► There is an overrepresentation of osteoporosis 
in high-dose statin treatment.
How might this impact on clinical practice or 
future developments?
 ► In clinical practice, high-risk patients for 
osteoporosis under high-dose statin treatment 
should be monitored more frequently.
AbsTrACT
Objective Whether HMG-Coa-reductase inhibition, 
the main mechanism of statins, plays a role in the 
pathogenesis of osteoporosis, is not entirely known so 
far. Consequently, this study was set out to investigate 
the relationship of different kinds and dosages of statins 
with osteoporosis, hypothesising that the inhibition of 
the synthesis of cholesterol could influence sex-hormones 
and therefore the diagnosis of osteoporosis.
Methods Medical claims data of all austrians from 
2006 to 2007 was used to identify all patients treated 
with statins to compute their daily defined dose averages 
of six different types of statins. We applied multiple 
logistic regression to analyse the dose-dependent risks 
of being diagnosed with osteoporosis for each statin 
individually.
results in the general study population, statin 
treatment was associated with an overrepresentation 
of diagnosed osteoporosis compared with controls (OR: 
3.62, 95% Ci 3.55 to 3.69, p<0.01). There was a highly 
non-trivial dependence of statin dosage with the ORs 
of osteoporosis. Osteoporosis was underrepresented 
in low-dose statin treatment (0–10 mg per day), 
including lovastatin (OR: 0.39, Ci 0.18 to 0.84, p<0.05), 
pravastatin (OR: 0.68, 95% Ci 0.52 to 0.89, p<0.01), 
simvastatin (OR: 0.70, 95% Ci 0.56 to 0.86, p<0.01) and 
rosuvastatin (OR: 0.69, 95% Ci 0.55 to 0.87, p<0.01). 
However, the exceeding of the 40 mg threshold for 
simvastatin (OR: 1.64, 95% Ci 1.31 to 2.07, p<0.01), 
and the exceeding of a 20 mg threshold for atorvastatin 
(OR: 1.78, 95% Ci 1.41 to 2.23, p<0.01) and for 
rosuvastatin (OR: 2.04, 95% Ci 1.31 to 3.18, p<0.01) 
was related to an overrepresentation of osteoporosis.
Conclusion Our results show that the diagnosis 
of osteoporosis in statin-treated patients is dose-
dependent. Thus, osteoporosis is underrepresented 
in low-dose and overrepresented in high-dose statin 
treatment, demonstrating the importance of future 
studies’ taking dose-dependency into account when 
investigating the relationship between statins and 
osteoporosis.
InTrOduCTIOn
Osteoporosis is a chronic disease characterised by 
a reduced bone mineral density (BMD) induced by 
an imbalance in osteoblastic and osteoclastic bone 
formation and resorption.1 Due to the elevated 
fracture risk, osteoporosis can have detrimental 
effects on a patient’s quality of life and is associ-
ated with a higher mortality and morbidity as well 
as being an economic burden.2 By now, numerous 
studies about osteoporosis and its treatment have 
been conducted—many of which revolve around 
the question whether statins affect bone metabo-
lism.3–10 Statins play a crucial role in the manage-
ment of hypercholesterolemia, which makes them 
a commonly used drug.11 Actual guidelines for 
the treatment of hypercholesterolemia in high-
risk patients suffering from cardiovascular disease 
(CVD) or diabetes have been issued, recommending 
cholesterol levels to be as low as possible.12 There-
fore, due to the sheer number of patients under 
statin therapy, research on the connection between 
statin usage and osteoporosis risk is of great impor-
tance. In particular, the underlying pathophysio-
logical mechanisms of a possible osteoprotective 
effect of statins have yet to be fully established.3 13 14 
Although many observational studies report posi-
tive effects of statin use on BMD and/or fracture 
risk, existing data do not sufficiently support the 
use of statins as osteoporosis prophylaxis. This 
is mainly due to the heterogeneity of the data 
concerning the effect of statin therapy on bone 
formation markers, BMD in females and overall 
BMD and fracture risk,3 as well as the lack of data 
regarding the relationship between different kinds 
and dosages of statins and diagnosis of osteoporosis. 
Another topic causing controversy is the question 
whether statins affect sex hormone levels such as 
testosterone or oestrogen.15–17 Statins act by inhib-
iting the endogenous synthesis of cholesterol, the 
main substrate for the synthesis of sex hormones, 
and thus we cannot disregard the possibility of a 
negative effect of statins on bone health, especially 
in higher dosages. However, data on the dosage-de-
pendency of statins in the diagnosis of osteoporosis 
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are sparse. Consequently, the present study seeks to investigate 
the relationship between different kinds and dosages of statins 
and osteoporosis and to shed light on the controversy regarding 
the relationship between statin treatment and the diagnosis of 
osteoporosis in a nationwide population-based study.
sTudy desIgn And MeTHOds
We conducted a cross-sectional retrospective analysis of the 
entire Austrian population using a consolidated administrative 
research data base.18
Patient population
Our data include all Austrians with health claims (roughly 97% 
of the population) for which data on all main and side diag-
noses from hospital stays and all prescriptions of drugs with 
costs that exceed a prescription charge of EUR 4.70 is available. 
We included patients with uniquely identifiable age and sex who 
were alive during the entire observation period from January 
2006 to December 2007 (n=7 945 775). Patients born in these 
years or with age >90 years were excluded to gain a more 
homogenous group of patients. The obtained cohort consisted of 
7 897 449 patients (male=3 702 572; female=4 194 877). Infor-
mation on prescriptions was available in the Anatomical Thera-
peutic Chemical (ATC) Classification System codes; to identify 
patients being diagnosed with osteoporosis, main and side diag-
noses from hospital stays were extracted as International Classi-
fication of Diseases, 10th revision (ICD10) codes. Patients with 
a main or side diagnosis from the range M80-M82 (including 
M80: ‘Osteoporosis with current pathological fracture’, M81: 
‘Osteoporosis without current pathological fracture’ and M82: 
‘Osteoporosis in diseases classified elsewhere’ (defined as osteo-
porosis in multiple myelomatosis or endocrine disorders) were 
classified as osteoporosis patients. We additionally conducted 
a sensitivity analysis to control for occurrences of rheumatoid 
arthritis (ICD10 code M06), ischaemic heart diseases (any code 
from the range I20–I25), diseases or arteries including arterioles 
and capillaries (I70–I79), stroke (I63, I64), diabetes (E10, E11), 
chronic renal insufficiency (N17–N19), nicotine dependency 
(F17), overweight and obesity (E65–E68), chronic obstructive 
pulmonary disease (J44), asthma (J45) and Crohn’s disease 
(K50).
Identifying patients with statin treatment
We identified all patients who had at least one prescription of 
any of the seven statins available on the market during the obser-
vation period: Simvastatin (ATC-code: C10AA01), Lovastatin 
(ATC-code: C10AA02), Pravastatin (ATC-code: C10AA03), 
Fluvastatin (ATC-code: C10AA04), Atorvastatin (ATC-code: 
C10AA05), Cerivastatin (ATC-code: A10AA06) and Rosuvas-
tatin (ATC-code: C10AA07). For these patients, we additionally 
controlled for possible effects of other prescribed drugs including 
49 different kinds of insulin-sparing or providing medication 
(all ATC-codes starting with A10) and 3 fibrates (ATC-code: 
C10AB02, C10B05, C10A×09).
For each medication, we tested if the patient was a regular 
drug user or not. Only if a patient had a minimum of four 
different prescription entries for a given drug, we identified him/
her as a valid drug user. As most health claims are filed on a 
quarterly basis, four different prescription entries are equivalent 
to a treatment regularly applied over 1 year. Medications with 
less than 35 valid patients were excluded. The control group was 
made up of all patients not treated with statins.
Average daily doses
The average daily dose of a given drug for each patient was 
calculated as the amount of the drug (converted from defined 
daily dose to mg1) divided by the number of treatment days 
that the patient did not spend in a hospital. Patients were then 
grouped according to their average daily dose for each statin in 
groups of >0–10 mg, >10–20 mg, >20–40 mg, >40–60 mg and 
>60–80 mg.
Patient and public involvement
Patients were not involved in the study design. Details of the 
ethical approval are provided in the online supplementary 
material.
Statistical analyses
We computed age-specific and sex-specific ORs between statin 
use and being diagnosed with osteoporosis. Multiple logistic 
regression was used to investigate this association while 
controlling for age, sex, dosage and prescription of other medi-
cations (drugs used in diabetes and fibrates). Next to age and sex, 
the independent variables in the regression included the dosage 
category for each type of statin or other medication as a cate-
gorical variable. Patients were assigned a categorical variable for 
each statin according to their average daily dose in milligrams. 
We controlled for other medications (20 glucose lowering drugs, 
including metformin; 3 fibrates) by introducing binary dummy 
variables for whether the patient fulfilled all criteria to be consid-
ered a valid drug user or not (see above). Goodness of fit of 
the regression models was evaluated by the adjusted R-squared 
statistic; the variance inflation factor (VIF) was used to test for 
multicollinearity.
resulTs
baseline characteristics
We identified 353 502 statin-treated patients (175 506 males, 
177 996 females) out of which 11 701 patients (1765 males, 
9936 females) were diagnosed with osteoporosis (for a detailed 
description of the osteoporotic population, see also online 
supplementary tables S1 and S2). The control group (no statin 
exposure) consisted of 7 543 947 patients (3 527 066 males, 
4 016 881 females), including 68 699 patients (10 410 males, 
58 289 females) diagnosed with osteoporosis. Table 1 presents 
the results of a sex-matched and age-matched cohort analysis 
of statin users in comparison to non-statin users and shows that 
statin users presented more often with a diagnosis of CVD, renal 
failure, nicotine dependency, overweight and obesity and were 
treated more often with antidiabetics.
sex-specific comparison of the diagnosis of osteoporosis
Within the whole study population, our results show that women 
are at a higher risk of being diagnosed with osteoporosis when 
compared with men (OR: 5.08, 95% CI 4.98 to 5.18, p<0.01; 
see also online supplementary table S3).
Comparison of the diagnosis of osteoporosis between 
patients with and without statin treatment
In the present analysis, the diagnosis of osteoporosis was more 
prevalent in patients of any age treated with statins when 
compared with control subjects without statin treatment (OR: 
3.62, 95% CI 3.55 to 3.69, p<0.01). In a sex-specific analysis, 
the diagnosis of osteoporosis was overrepresented in both statin-
treated females (OR(f): 3.90, 95% CI 3.81 to 3.98, p<0.01) and 
males (OR(m): 3.35, 95% CI 3.18 to 3.52, p<0.01). Therefore, 
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Table 1 Baseline characteristics of the study population matched 
for age and sex
statin Matched control
Male Female Male Female
N 175 506 177 996 526 518 533 988
Age (mean±SD) 65.02±10.89 69.02±10.46 65.02±10.89 69.02±10.46
Osteoporosis (M80–M82) 1765
(1.01%)
9936
(5.58%)
5.264
(1.00%)
26.903
(5.04%)**
Insulin 11 690
(6.66%)
12 332
(6.93%)
8603**
(1.63%)
8617**
(1.61%)
Oral antidiabetics 34 511
(19.66%)
32 514
(18.27%)
32 569**
(6.19%)
31 237**
(5.85%)
Fibrates 3667
(2.09%)
1993
(1.12%)
6470**
(1.23%)
8131**
(1.52%)
Arthritis (M06) 359
(0.20%)
991
(0.56%)
988
(0.19%)
2.703*
(0.51%)
CVD (I20–I25) 36 970
(21.06%)
23 998
(13.48%)
33 971
(6.45%)
27 814**
(5.21%)
Stroke (I63, I64) 5164
(2.94%)
4429
(2.49%)
8250**
(1.57%)
7875**
(1.47%)
Diseases of arteries (I70–I79) 12 513
(7.13%)
9058
(5.09%)
17 621**
(3.35%)
13 605**
(2.55%)
Renal failure (N17–N19) 8148
(4.64%)
6684
(3.76%)
15 774**
(3.00%)
14 039**
(2.63%)
Overweight and obesity (E66) 8314
(4.74%)
8290
(4.66%)
10 913**
(2.07%)
13 526**
(2.53%)
Nicotine dependency (F17) 4.215
(2.40%)
1766
(0.99%)
6925**
(1.32%)
2422**
(0.45%)
We give group size, age and the absolute and relative frequencies of osteoporosis, use of other 
medications (insulin, metformin, fibrates) and comorbid conditions for males and females in the statin-
treated and control group, respectively.
**P<0.01; *p<0.05.
CVD, cardiovascular disease.
Figure 1 Age-dependent, sex-specific ORs for osteoporosis and statin 
use. Statin-related osteoporosis risks increase with younger age and 
female sex.
Figure 2 Dosage dependency of the statin—osteoporosis association. 
While low doses of statin can even be related to decreased osteoporosis 
risks, the disease risk clearly increases for higher doses.
the ORs for females were significantly increased with respect 
to males (p<0.01; see also online supplementary table S3). 
After stratifying the patients by their age in 10-year-intervals, 
we obtained similar results (osteoporosis being overrepresented 
in statin-treated individuals with significantly stronger effects in 
females than males) (see figure 1 and online supplementary table 
S3). In addition, figure 1 presents that in the age-class of 40–50 
years, the relationship between statin treatment and increased 
odds of osteoporosis is stronger than in all other age groups.
Comparison of the different dosages of statins in the 
diagnosis of osteoporosis
There is a highly non-trivial dependence of statin dosage 
with the odds of osteoporosis. For low dose statin treat-
ment (0–10 mg) osteoporosis is underrepresented in simvas-
tatin (OR: 0.70, 95% CI 0.56 to 0.86, p<0.01), lovastatin 
(OR: 0.39, 95% CI 0.18 to 0.84, p<0.05), pravastatin (OR: 
0.68, 95% CI 0.52 to 0.89, p<0.01) and rosuvastatin (OR: 
0.69, 95% CI 0.55 to 0.87, p<0.01). However, the relation-
ship between statin treatment and osteoporosis reverses with 
increased dosages. Particularly, this is the case for simvastatin, 
atorvastatin and rosuvastatin (note that for the remaining 
types of statin the patient numbers were too low to reliably 
estimate dosage -dependence) (see figure 2 and table 2). There 
we show that the diagnosis of osteoporosis was overrepre-
sented in the group treated with >40–60 mg of simvastatin 
per day (OR: 1.64, 95% CI 1.31 to 2.07, p<0.01) and further 
increased with the increase of the daily dosage (>60–80 mg 
simvastatin: OR: 3.30, 95% CI 2.36 to 4.62, p<0.01). The 
fact that the diagnosis of osteoporosis was overrepresented 
in higher dosages of statin treatment could be also observed 
for atorvastatin (>10–20 mg: OR: 1.35, 95% CI 1.11 to 
1.64, p<0.01; >20–40 mg: OR: 1.78, 95% CI 1.41 to 2.23, 
p<0.01; >40–60 mg: OR: 2.12, 95% CI 1.47 to 3.06, p<0.01; 
>60–80 mg: OR: 3.14, 95% CI 1.77 to 5.56, p<0.01) and for 
rosuvastatin (>20–40 mg: OR: 2.04, 95% CI 1.31 to 3.18, 
p<0.01); the detailed description of the relationship of the 
dosages of statins with the diagnosis of osteoporosis with frac-
ture is presented in online supplementary table S4. As demon-
strated in online supplementary table S6, age was homogenous 
distributed over the different groups of statins.
To investigate whether the dosage-dependent relationship 
between statin use and osteoporosis risk as shown in figure 2 
might be confounded by comorbidities such as arthritis, CVD, 
diseases of the arteries, stroke, diabetes, renal failure, nico-
tine dependence, overweight and obesity, and diseases possibly 
treated with corticosteroids such as asthma, Crohn’s disease 
or chronic obstructive pulmonary disease, we repeated the 
logistic regression analysis while excluding all patients with 
the given comorbidity, see online supplementary files (baseline 
tests, including online supplementary figures S2–S7). We find 
that the exclusion of these patients does not change the results 
qualitatively. All considered regression models have adjusted 
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Table 2 Individual statin dosage-dependent ORs of osteoporosis (95% CI) obtained from the logistic regression model
All lovastatin Fluvastatin Pravastatin simvastatin Atorvastatin rosuvastatin
0–10 mg 0.39* 1.00 0.68** 0.70** 1.04 0.69**
CI 0.18 to 0.84 1.00 to 1.00 0.52 to 0.89 0.56 to 0.86 0.86 to 1.25 0.55 to 0.87
10–20 mg 1.06 0.59** 0.87 0.83 1.35** 0.90
CI 0.68 to 1.64 0.42 to 0.82 0.70 to 1.07 0.68 to 1.02 1.11 to 1.64 0.71 to 1.15
20–40 mg 1.59 0.85 1.01 1.07 1.78** 2.04**
CI 0.83 to 3.07 0.69 to 1.04 0.81 to 1.26 0.87 to 1.32 1.41 to 2.23 1.31 to 3.18
40–60 mg   0.91   1.64** 2.12**   
CI   0.74 to 1.11   1.31 to 2.07 1.47 to 3.06   
60–80 mg   1.09   3.30** 3.14**   
CI   0.87 to 1.35   2.36 to 4.62 1.77 to 5.56   
Adj. R2 0.94 0.94 0.94 0.93 0.95 0.94
Max. VIF 4.21 3.26 3.04 2.74 2.87 3.29
**P<0.01; *p<0.05.
The bold values represent the significant results.
VIF, variance inflation factor.
R-squared statistics from the range 0.71–0.96 (see table 2 and 
online supplementary table S5). To test for multicollinearity, 
we considered the VIF for each variable and found the 
maximum value to be 4.21, indicating that multicollinearity is 
not an issue in the data (see table 2 and online supplementary 
table S5).
sex-specific analysis
In a sex-specific analysis, the obtained results could be confirmed 
with slight differences as described in detail in the online supple-
mentary material (see online supplementary table S5 and figure 
S1.
dIsCussIOn
The aim of the present study was to investigate the relationship 
of statin therapy with osteoporosis. Our results showed that 
osteoporosis was overrepresented in statin-treated patients in 
the general study population. Thus, by splitting the study cohort 
in the different kinds of statins and dosages, there was a dose-de-
pendent relationship with a diagnosed osteoporosis. Therefore, 
our results which showed that the diagnosis of osteoporosis was 
overrepresented in high-dose and underrepresented in low-dose 
statin treatment seem to be of great importance as they first 
show that it is important to analyse the different dosages and 
substances of statins.
Several studies have investigated whether HMG-CoA reduc-
tase inhibition, the main mechanism of statins, affects BMD. 
However, one of the main limitations of existing studies is that 
they did not investigate the relationship between the different 
kinds of statins (including potency and dosages) and the occur-
rence of osteoporosis in detail. A recent meta-analysis concluded 
that statin treatment had a tendency towards a positive effect 
on the reduction of fracture risk and marked improvement of 
BMD in statin-treated patients.3 A large meta-analysis conducted 
in Taiwan, including 45 342 patients in the statin cohort and 
115 594 patients in the control cohort, stated that statin therapy 
correlates with a decreased risk of osteoporosis when taken daily 
over a longer period of time, however, also not accounting for 
the different types of statins and their dosages.7 In the present 
study, there was an increased risk of being diagnosed with osteo-
porosis in the general study population of statin-treated patients 
when compared with controls. However, the risk of being 
diagnosed with osteoporosis under statin-treatment decreased 
as a function of age, which could indicate that a longer statin 
treatment could be related to a lower occurrence of the diagnosis 
of osteoporosis. To the best of our knowledge, this is the first 
study which shows that it is important to consider the different 
kinds of substances and dosages when investigating the relation-
ship of osteoporosis and statin therapy. Therefore, we could 
show that low-dose statin treatment with daily dosages lower or 
equal to 10 mg of pravastatin, lovastatin, simvastatin and rosu-
vastatin was related to an underrepresentation of osteoporosis. 
Lin et al also compared different types of statins but did not 
investigate the effects of different daily dosages of the statins on 
the prevalence rate of osteoporosis. Thus, in their study, they 
investigated the effect of statins on the probability of developing 
new-onset osteoporotic fractures (NOFs) and concluded that a 
therapy with rosuvastatin and atorvastatin was related to a risk 
reduction of NOFs, significantly stronger when compared with 
simvastatin treatment.8 However, our results demonstrate that it 
is important to analyse the different kinds and dosages of statins. 
Rejnmark et al compared 124 655 fracture cases with 373 962 
controls and found out that patients who had a fracture were 
less likely to use statins than the controls.19 In accordance with 
these findings, the present study also demonstrates an underrep-
resentation of osteoporosis in statin-treated patients, but only in 
patients on low dose statin therapy and not on high dose treat-
ment of at least 1 year. Therefore, the increase of the dosage of 
statins was related to an overrepresentation of osteoporosis. A 
retrospective cohort study by Ward et al also omitted specifying 
the type of statin when comparing the fracture incidence of 6967 
patients taking statins vs an equal number of controls. About 
one third of the patients received maximum dosages for simvas-
tatin, pravastatin and atorvastatin, which were defined as 80 mg, 
and 40 mg for rosuvastatin. Although statins seem to decrease 
the risk of femoral neck fractures, there was no difference in 
the overall fracture risk when compared with the controls.20 In 
light of numerous publications presenting rather heterogenous 
results while pursuing the same research question, we attempted 
to propose additional explanations for the observed discrepan-
cies. Likely causes for different conclusions about whether or 
not statins are beneficial for bone health among various studies 
might be genetic determinants concerning CYP19A1/aromatase 
levels21 as this enzyme is responsible for the peripheral conver-
sion of testosterone to oestrogen. It is a well-known fact that 
females are more commonly diagnosed with osteoporosis when 
compared with males, which was also the case in the present 
study. Furthermore, it is also known that the risk of osteoporosis, 
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including a higher risk of bone fractures, is especially high in 
postmenopausal women.22 In the postmenopausal state, oestra-
diol plays a crucial role in the maintenance of BMD23 and, thus, 
one has to keep in mind that oestrogens are cholesterol deri-
vates24 and play a significant role in bone metabolism by inhib-
iting bone resorption.25 Thus, whether higher dosages of statins 
could inhibit the synthesis of sex hormones, via HMG-CoA-re-
ductase inhibition, is of special interest, as we could show that an 
increase in the dosages of statins was related to an exaggerated 
increase and overrepresentation of diagnosed osteoporosis cases 
in the whole study population, and additionally significantly 
stronger in women than when compared with men. Women, 
especially due to lower oestrogen levels in the post menopause, 
are more likely to have an insufficient BMD.26 27 In men, free 
testosterone levels are positively associated with higher levels 
of BMD and inversely related to bone turnover markers.28 The 
sex-specific differences in the pathogenesis of osteoporosis, a 
decreased activity of osteoblasts in men and an increased bone 
resorption due to a lack of oestrogen in women, would support 
the theory posed above.3 In mice models, statins have been 
shown to reduce plasma levels of testosterone, oestradiol and 
progesterone, while raising levels of follicle stimulating hormone 
and luteinising hormone at the same time;29 similar results have 
also been presented in cell lines.30 In the Rotterdam study, the 
effect of statins in 4166 men on sexual hormones was inves-
tigated and the authors could prove that statin treatment was 
related to lower serum total and non-sexual hormone-binding 
globulin (SHBG)-bound testosterone levels.31 Lower testos-
terone levels under statin therapy were also observed in other 
studies.15–17 Another study has shown that higher levels of SHBG 
are associated with a decrease in BMD.28 Taken together, these 
findings suggest a connection between sex hormone levels and 
statins in the pathogenesis of osteoporosis.
There are limitations and strengths in the present study which 
have to be discussed. Limitations of our study include that the 
data extracted from the patient contingent only show the current 
dosage the patients are taking. However, only patients who 
had a statin treatment for a minimum of 1 year were included. 
Another limitation is that we could not confirm the diagnosis 
of osteoporosis, for example, with bone densitometry data, and 
that we had no access to relevant treatments such as corticoste-
roids, hormonal replacement therapy or bisphosphonates. Addi-
tionally, one has to keep in mind that diseases such as CVD, 
which are commonly treated with statins, are related to other 
diseases and conditions such as diabetes, physical inactivity, nico-
tine abuse or lack of hormone treatment in the menopause, all 
factors directly related to osteoporosis. A strength is that the 
compliance of the patients could be evaluated due to the data 
about the prescriptions of statins per year. Another strength is 
that the study investigated the general Austrian population and, 
therefore, the number of statin-treated patients is high.
COnClusIOn
In conclusion, our data suggest that osteoporosis is overrep-
resented in high-dosage, but underrepresented in low-dosage 
statin treatment. Guidelines for cholesterol lowering therapies 
for prevention of cardiovascular complications advise to reduce 
plasma low-density lipoprotein (LDL-cholesterol) levels as low 
as 70 mg/dL in high risk populations.12 We propose that moni-
toring high-risk patients, that is, postmenopausal female patients 
under high-dosage statin therapy, might be useful in order to 
offer an individual therapy to prevent or treat osteoporosis. 
Thus, larger and prospective studies with a focus on dosages of 
statins should be conducted in order to clarify the relationship 
with osteoporosis.
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